Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corcept Therapeutics recently completed a clinical study titled An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Characterize the Impact of the Cytochrome P450 3A Inhibitor Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Subjects. The study aimed to understand how repeated doses of itraconazole affect the pharmacokinetics, safety, and tolerability of single doses of dazucorilant in healthy adults, which is significant for optimizing drug interactions and safety profiles.
The intervention involved administering dazucorilant, a drug in 75 mg soft gelatin capsules, and itraconazole, a 100 mg capsule, to participants. The purpose was to assess the interaction between these drugs when taken together.
This Phase 1 study was interventional, with a single-group assignment. There was no masking, and the primary purpose was treatment. Participants received specific doses of the drugs over a set schedule to monitor interactions.
The study began on May 31, 2024, and was last updated on June 29, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data collection and analysis.
The completion of this study could influence Corcept Therapeutics’ stock performance by providing new insights into drug safety and efficacy, potentially boosting investor confidence. In the competitive pharmaceutical industry, such updates are vital for maintaining a competitive edge.
The study is completed, with further details available on the ClinicalTrials portal.